Geeta Jain
Head of Investor Relations
Replay available
Definium Therapeutics, Inc. (DFTX) Q2 2026 Earnings Call
Definium Therapeutics, Inc. (NASDAQ: DFTX) Q2 2026 earnings conference call, held 2026-08-06. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Rob Barrow
Chief Executive Officer
Dr. Dan Carlin
Chief Medical Officer
Matt Wiley
Chief Commercial Officer
Brandy Roberts
Chief Financial Officer
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Definium Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:01.165 -- 00:00:05.528 Good afternoon. I am Geeta Jain, Head of Investor Relations, and I want to thank you 00:00:05.528 -- 00:00:10.251 for joining us today for Definium Therapeutics' second quarter 2026 00:00:10.251 -- 00:00:13.674 financial results and recent highlights conference call. 00:00:13.674 -- 00:00:18.057 All participants are in listen-only mode. This webcast is live on the Investor section 00:00:18.057 -- 00:00:21.399 of Definium's webcast at definiumtx.com, 00:00:21.399 -- 00:00:25.130 and a replay will be available after the webcast. 00:00:25.130 -- 00:00:29.155 Leading the call today will be Rob Barrow, our Chief Executive Officer, who is joined 00:00:29.155 -- 00:00:34.261 by Dr. Dan Carlin, our Chief Medical Officer, Brandy Roberts, our Chief Financial 00:00:34.261 -- 00:00:38.307 Officer, and Matt Wiley, our Chief Commercial Officer. 00:00:38.307 -- 00:00:42.031 During today's call, we will be making certain forward-looking statements, including, 00:00:42.031 -- 00:00:46.936 without limitation, statements about the potential safety, efficacy, and regulatory and 00:00:46.936 -- 00:00:51.922 clinical progress of our product candidates, our anticipated cash runway, and our future 00:00:51.922 -- 00:00:55.806 expectations, plans, partnerships, and prospects. 00:00:55.806 -- 00:00:59.730 These statements are subject to various risks, such as changes in market conditions and 00:00:59.730 -- 00:01:05.194 difficulties associated with research and development and regulatory approval processes. 00:01:05.194 -- 00:01:09.698 These and other risk factors are described in the filings made with the SEC and the applicable 00:01:09.698 -- 00:01:15.103 Canadian securities regulators, including our annual report on Form 10-K and Form 10-Q 00:01:15.103 -...